# A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)

> **NCT01254630** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 5305 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** V212
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01254630
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-24
- **Primary completion:** 2017-04-11
- **Final completion:** 2017-04-11
- **Target enrollment:** 5305 (ACTUAL)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254630, "A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01254630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*